Isis Pharmaceuticals and Hybridon have announced the cancellation of the remaining financial obligations related to their Collaboration and License Agreement that the companies completed in May 2001. Under the original agreement, Hybridon owed Isis an additional 4 million shares of Hybridon common stock, payable immediately. Isis owed Hybridon $4.5 million in cash or stock, due Read more about Isis And Hybridon Cancel Reciprocal Financial Obligations[…]